Program Overview

Program Overview (cont)

Defining the Unmet Needs in Breast Cancer
ESMO Guidelines in ER-Positive/HER2-
Negative MBC
ESMO Guidelines in First- and Second-Line
HER2-Positive MBC
ESMO Guidelines in Third-Line HER2-
Positive MBC and Beyond
ESMO Guidelines in mTNBC
Latest Clinical Data for ER Targeting in
Breast Cancer
Mechanisms of Endocrine Resistance and
Therapeutic Strategies
CDK 4/6 Inhibitor Phase 3 Registration
Studies
Similar Global Efficacy Results
CDK 4/6 Inhibitors in the First-Line Setting
MONALEESA-2
CDK 4/6 Inhibitors in the Second- and Third-
Line Settings
BOLERO-2 and SOLAR-1 Trials
SERMs and SERDs vs AIs
Clinical Efficacy of SERMs, SERDs, and AIs
in MBC
Early Trials With Oral SERDs
EMERALD
Study Design
EMERALD
PFS
PARP Inhibitors in gBRCA Early Breast
Cancer
Targeting PARP in BC
BROCADE3
Study Design
BROCADE3: Primary Endpoint
PFS by IA
Germline Mutations in PALB2
Platinum/Veliparib Compounds in eTNBC
BrighTNess Study Design
Platinum/Veliparib Compounds in eTNBC
BrighTNess: pCR and EFS at 4.5 Years
BROCADE3: Primary Endpoint
PFS by IA
PARP Inhibitors in the Neoadjuvant Setting
OlympiA
Study Design
OlympiA
IDFS and OS (ITT)
The Growing Role of Second-Generation
ADCs in Breast Cancer
Mechanism of Action of ADCs
Overview of ADCs in Development for
Breast Cancer
New ADCs in TNBC
Sacituzumab Govitecan
New ADCs in TNBC: Sacituzumab
Govitecan
ASCENT Trial
New ADCs in TNBC
Datopotamab Deruxtecan
New ADCs in HR-Positive BC
HER3 as a Therapeutic Target for BC
New ADCs Against HER3
Patritumab Deruxtecan
Ladiratuzumab Vedotin
Ladiratuzumab Vedotin in Combination With Pembrolizumab
HER2-Low Breast Cancer
HER2 Is Difficult to Measure Even After 20
Years
Emerging HER2 Paradigm Shift
HER2 "Negative"
HER2 Status and Benefit From Adjuvant
Trastuzumab
Activity of 2 Anti-HER2 Agents in Patients
With HER2-Negative BC With Low
Expression of HER2
Definition of HER2-Low
Trastuzumab Duocarmazine
Trastuzumab Deruxtecan
DESTINY-Breast04
T-DXd vs Chemotherapy in Previously
Treated HER2-Low BC
HER2-Positive Breast Cancer
Current Treatment Landscape for HER2-
Positive BC
New Anti-HER2 Opportunities
New Anti-HER2 Opportunities
New TKIs
Trial Designs and Positive PFS Data
New TKIs
OS Data
New TKIs
OS Data in Patients With BMs and TEAEs
Trastuzumab-Deruxtecan (cont)
Trastuzumab Deruxtecan
DESTINY-Breast01 Phase 2 Study
AEs of Special Interest
Interstitial Lung Disease
DESTINY-Breast03
First Randomized, Phase 3 Study of T-DXd
DESTINY-Breast03
Primary Endpoint: PFS by BICR
DESTINY-Breast03
Confirmed ORR and Best Overall Response
DESTINY-Breast03
Drug-Related TEAEs in ≥ 20% of Patients
DESTINY-Breast03
AEs of Special Interest
TULIP: Trastuzumab Duocarmazine vs
Physician’s Choice
Randomized Phase 3 Study
Immunotherapy
Randomized Phase 3 Studies With
Chemotherapy and PD-1/PD-L1 Inhibitors:
Study Designs
IMpassion130
Nab-Paclitaxel + Atezolizumab vs Nab-
Paclitaxel + PBO
IMpassion131
Atezolizumab + Paclitaxel vs PBO +
Paclitaxel
KEYNOTE-355
Pembrolizumab + Chemo vs Pembrolizumab
+ PBO
KEYNOTE-355
Final OS
Targeted Therapies Being Investigated in
Combination With IO
Role of Adjuvant ICI in Patients With
eTNBC
KEYNOTE-522: Study Design
KEYNOTE-522
Results
GeparNUEVO
Study Design
GeparNUEVO
Results
Role of Adjuvant ICI in Patients Who
Achieved pCR After Neoadjuvant Therapy
Remaining Questions
Upcoming ASCO 2022 Meeting
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022
Data Expected to Be Presented at ASCO
2022